# Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy

Source: https://onco.cc/trials/nct05764928/  
OnCo record `nct05764928` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in lung cancer, run by Rgene Corporation, not yet recruiting.

## Summary

Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy is a phase 1/2, interventional study registered as NCT05764928 by Rgene Corporation, with a registry enrolment figure of 32 participants, started 2026-12-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: BLEX 404. Conditions listed: Nonsquamous Nonsmall Cell Neoplasm of Lung. Primary outcome: DLT determination; RDL Determination; Overall response rate (PR + CR) after 4 cycles of combination use. Lung eligibility wording from the registry: "Naïve patients with histologically or pathologically diagnosed with Advanced Inoperable or Metastatic non-small cell lung cancer and intended for first line treatment". Sites: Taiwan. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05764928
- Phase: 1/2
- Setting: A Phase I/II, Open Label Study to Evaluate the Safety and Efficacy of BLEX 404Oral Liquid Combined With Pemetrexed + Cisplatin Therapy in Patients With Advanced Inoperable or Metastatic EGFR Wild-type Non-Small Cell Lung Cancer Patients
- Sponsor: Rgene Corporation
- Enrolled: 32

## Sources

- ClinicalTrials.gov NCT05764928: https://clinicaltrials.gov/study/NCT05764928

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05764928.json